Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · Real-Time Price · USD
0.2060
-0.0140 (-6.36%)
At close: Mar 28, 2025, 4:00 PM
0.2048
-0.0012 (-0.58%)
After-hours: Mar 28, 2025, 4:55 PM EDT

Adaptimmune Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Revenue
178.0360.2827.156.153.96
Upgrade
Revenue Growth (YoY)
195.34%122.05%341.50%55.36%252.76%
Upgrade
Cost of Revenue
149.13126.51127.73111.0991.57
Upgrade
Gross Profit
28.9-66.23-100.58-104.94-87.61
Upgrade
Selling, General & Admin
81.3164.4663.3957.3145.8
Upgrade
Operating Expenses
81.3164.4663.3957.3145.8
Upgrade
Operating Income
-52.41-130.69-163.97-162.25-133.41
Upgrade
Interest Expense
-3.35----
Upgrade
Interest & Investment Income
6.65.961.541.12.31
Upgrade
Currency Exchange Gain (Loss)
-1.73-0.81-0.543.851.11
Upgrade
Other Non Operating Income (Expenses)
----0.01-0.03
Upgrade
EBT Excluding Unusual Items
-50.89-125.54-162.96-157.31-130.02
Upgrade
Merger & Restructuring Charges
-5.95-9.05---
Upgrade
Gain (Loss) on Sale of Investments
---0.010.09
Upgrade
Asset Writedown
-10.4----
Upgrade
Other Unusual Items
-22.05---
Upgrade
Pretax Income
-67.24-112.54-162.96-157.3-129.93
Upgrade
Income Tax Expense
3.581.342.50.790.16
Upgrade
Net Income
-70.81-113.87-165.46-158.09-130.09
Upgrade
Net Income to Common
-70.81-113.87-165.46-158.09-130.09
Upgrade
Shares Outstanding (Basic)
252201161156142
Upgrade
Shares Outstanding (Diluted)
252201161156142
Upgrade
Shares Change (YoY)
25.48%24.73%3.47%9.37%35.72%
Upgrade
EPS (Basic)
-0.28-0.57-1.03-1.01-0.91
Upgrade
EPS (Diluted)
-0.30-0.57-1.03-1.02-0.91
Upgrade
Free Cash Flow
-74.09-145.56-171.272.16-55.93
Upgrade
Free Cash Flow Per Share
-0.29-0.72-1.060.01-0.39
Upgrade
Gross Margin
16.23%-109.86%---
Upgrade
Operating Margin
-29.44%-216.81%-603.97%-2638.58%-3370.52%
Upgrade
Profit Margin
-39.78%-188.90%-609.46%-2570.99%-3286.81%
Upgrade
Free Cash Flow Margin
-41.62%-241.47%-630.86%35.05%-1413.14%
Upgrade
EBITDA
-41.18-120.85-157.89-155.68-125.81
Upgrade
EBITDA Margin
-23.13%-200.48%---
Upgrade
D&A For EBITDA
11.239.846.086.577.59
Upgrade
EBIT
-52.41-130.69-163.97-162.25-133.41
Upgrade
EBIT Margin
-29.44%-216.81%---
Upgrade
Revenue as Reported
178.0360.2827.156.153.96
Upgrade
Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q